{"slug":"vip-postherpetic","verification":{"valid":true,"entries":2,"head":"6ad62d7580dfbc25c6a57a421c1efd9158cc1df1b02331e6155168f5e3a2c78a"},"energy":{"passes":2,"tokens_in":22747,"tokens_out":2853,"tokens_total":25600,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"6ad62d7580dfbc25c6a57a421c1efd9158cc1df1b02331e6155168f5e3a2c78a"},"provenance":[{"ts":"2026-06-29T22:22:41.944Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Postherpetic\nSlug: vip-postherpetic\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **VIP** → immune / autonomic\",\"section_headings\":[\"What's breaking down\",\"Why VIP might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weig","response":"{\n  \"slug\": \"vip-postherpetic\",\n  \"title\": \"VIP for Postherpetic Neuralgia: Evidence Review\",\n  \"body\": \"## What's breaking down\\n\\nPostherpetic neuralgia follows shingles, an outbreak of the varicella-zoster virus. The virus reactivates in sensory ganglia, travels along nerves, and causes inflammation plus direct neuronal damage. Pain persists after the rash clears because damaged nerve fibers send scrambled or amplified signals. Layers include peripheral nerve fiber loss, central sensitization in the spinal cord, ongoing low-grade inflammation, and possible autonomic fiber disruption that affects local blood flow and sweating.\\n\\nIf nerve repair lags behind ongoing irritation, symptoms continue. VIP research focuses on immune balance and autonomic signaling rather than direct pain masking.\\n\\n## Why VIP might help you\\n\\nVIP is discussed for the immune and autonomic layer. If your postherpetic pain involves persistent inflammation around damaged nerves or altered autonomic control of blood flow, the following logic applies.\\n\\n1. Damaged nerves after shingles show changes in neuropeptide expression, including VIP.\\n2. VIP acts on receptors that dampen pro-inflammatory cytokines in preclinical models.\\n3. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nAnimal work shows VIP rises in injured nerves and may support local blood flow regulation. Human data on this exact use remain absent.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **VIP** → immune / autonomic\\n\\n## What the evidence actually shows\\n\\nNo published human clinical trials test VIP specifically for postherpetic neuralgia. Studies instead examine VIP expression after nerve injury or its anti-inflammatory effects in other models.\\n\\nOne 1990 study measured VIP in human sural nerves a","tokens_in":22747,"tokens_out":2853,"cost":0,"prev":"genesis","hash":"1fb074b86a59245bd4ae0955a80653e883b0f14e22fd50baf19c1a26bfcc734c"},{"ts":"2026-07-17T02:43:26.599Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-postherpetic","response":"34 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1fb074b86a59245bd4ae0955a80653e883b0f14e22fd50baf19c1a26bfcc734c","hash":"6ad62d7580dfbc25c6a57a421c1efd9158cc1df1b02331e6155168f5e3a2c78a"}]}